Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease

  • Fabio Efficace
    Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome Italy
  • Franco Mandelli
    Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome Italy
  • Paola Fazi
    Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome Italy
  • Cristina Santoro
    Department of Cellular Biotechnologies and Hematology University of Rome “Sapienza” Rome Italy
  • Gianluca Gaidano
    Division of Hematology, Department of Translational Medicine University of Eastern Piedmont Novara Italy
  • Francesco Cottone
    Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome Italy
  • Alessandra Borchiellini
    Hemostasis/Thrombosis Unit and Hemophilia Centre Città Della Salute E Della Scienza Molinette Turin Italy
  • Monica Carpenedo
    Hematology and Bone Marrow Transplantation, University of Milano‐Bicocca, San Gerardo Hospital, Monza Italy
  • Maria Pina Simula
    Hematology and Bone Marrow Transplantation Unit Ospedale Oncologico di Riferimento Regionale Armando Businco Cagliari Italy
  • Valeria Di Giacomo
    Divisionof Hematology Azienda Ospedaliera Papardo Messina Italy
  • Micaela Bergamaschi
    Clinica Ematologica IRCCS AOU San Martino IST, Genova Italy
  • Iolanda Donatella Vincelli
    Hematology Azienda Ospedaliera Bianchi‐Melacrino‐Morelli Reggio Calabria Italy
  • Francesco Rodeghiero
    Scientific Director Hematology Project Foundation Vicenza Italy
  • Marco Ruggeri
    Department of Cell Therapy and Hematology San Bortolo Hospital Vicenza Italy
  • Laura Scaramucci
    Department of Haematology S. Eugenio Hospital Rome Italy
  • Alessandro Rambaldi
    Department of Scienze Cliniche E Di Comunità University of Milan, Hematology and Bone Marrow Transplant Unit, ASST‐Ospedale Papa Giovanni XXIII Bergamo Italy
  • Nicola Cascavilla
    Department of Haematology and Stem Cell Transplantation Unit IRCCS ‘Casa Sollievo Della Sofferenza’ Hospital San Giovanni Rotondo Italy
  • Fabio Forghieri
    Department of Oncology, Hematology and Respiratory Diseases Section of Hematology, University of Modena and Reggio Emilia, Azienda Ospedaliero‐Universitaria Policlinico Modena Italy
  • Annamaria Petrungaro
    Division of Hematology University of Messina Messina Italy
  • Paolo Ditonno
    Hematology Unit “Di Venere” Hospital Bari Italy
  • Giovanni Caocci
    Department of Medical Sciences University of Cagliari Cagliari Italy
  • Sonia Cirrincione
    Unit of Transfusion and Hematology Treviglio Hospital Treviglio Italy
  • Maria Gabriella Mazzucconi
    Department of Cellular Biotechnologies and Hematology University of Rome “Sapienza” Rome Italy

抄録

<jats:p>The main objective of this study was to compare health‐related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic patients). Fatigue was also investigated as a secondary objective. Overall, 424 adult patients were enrolled in a multicenter observational study and the control group consisted of a representative sample from the general population. Propensity score matching plus further multivariate linear regression adjustment was used to compare HRQOL outcomes between pITP patients and general population. Mean age of patients was 54 years. Of those with HRQOL assessment, 99 patients (23.6%) were newly diagnosed, 53 (12.6%) were persistent, and 268 (63.8%) were chronic pITP patients. Comparison by patient group versus their respective peers in the general population revealed greater impairments in persistent pITP patients. Persistent pITP patients reported clinically meaningful impairments in physical functioning (−15; 95% CI −24.1 to −5.8; <jats:italic>P</jats:italic> = 0.002), social functioning (−15.3; 95% CI −25.5 to −5.1; <jats:italic>P</jats:italic> = 0.004), role physical (−28.4; 95% CI −43.1 to −13.7; <jats:italic>P</jats:italic> < 0.001), role emotional (−23.9; 95% CI −40.1 to −7.7; <jats:italic>P</jats:italic> = 0.004), and mental health scales (−11.3; 95% CI −21.2 to −1.4; <jats:italic>P</jats:italic> = 0.026) of the SF‐36 questionnaire. Higher fatigue severity was associated with lower physical and mental HRQOL outcomes. Our findings suggest that the burden of the disease and treatment might depend on the disease phase and that persistent pITP patients are the most vulnerable subgroup. Am. J. Hematol. 91:995–1001, 2016. © 2016 Wiley Periodicals, Inc.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ